|
1)
Immunohistochemical analysis of
pRb2/p130, VEGF, EZH2, p53, p16(INK4A), p27(KIP1), p21(WAF1), Ki-67
expression patterns in gastric cancer.
Mattioli E, Vogiatzi P, Sun A,
Abbadessa G, Angeloni G, D'Ugo D, Trani D, Gaughan JP, Vecchio FM,
Cevenini G, Persiani R, Giordano A, Claudio PP.
J Cell Physiol.
2007 Jan;210(1):183-91.
2)
A small molecule based on the
pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle
arrest and tumor growth reduction in vivo.
Bagella L, Sun A, Tonini T,
Abbadessa G, Cottone G, Paggi MG, De Luca A, Claudio PP, Giordano A.
Oncogene.
2007 Mar 22;26(13):1829-39. Epub 2006 Oct 16.
3)
Viral infections as a cause of
cancer (review).
Carrillo-Infante C, Abbadessa
G, Bagella L, Giordano A.
Int J Oncol.
2007 Jun;30(6):1521-8. Review.
4)
The efficacy of hybrid
chemotherapy with intravenous oxaliplatin and folinic acid and
intra-hepatic infusion of 5-fluorouracil in patients with colorectal
liver metastases: a phase II study.
Carnaghi C, Santoro A, Rimassa
L, Doci R, Rosati R, Pedicini V, Gullo G, Zuradelli M, Abbadessa G,
Morenghi E, Marcon I, Garassino I.
Invest New Drugs.
2007 Oct;25(5):479-85.
5)
Antiangiogenic drugs currently
used for colorectal cancer: what other pathways can we target to prolong
responses?
Abbadessa G, Vogiatzi P,
Rimassa L, Claudio PP.
Drug News Perspect.
2007 Jun;20(5):307-13. Review.
|